Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A rare-disease team designing a pediatric plan cannot treat a boxed-warning proposal from the review division as incidental context on CMC comparability package for a site change. CMC change-control owner must close to drop a secondary from that extract under Pharma & Life Sciences / CMC and Development Pathways.

DECISION CMC change-control owner in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. CMC change-control owner can defend Proceed under protocol from CMC comparability package for a site change after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in CMC comparability package for a site change — reopen intake, do not close to drop a secondary. 4. Two facts in CMC comparability package for a site change after a boxed-warning proposal from the review division conflict for CMC change-control owner; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a boxed-warning proposal from the review division. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for CMC change-control owner in a rare-disease team designing a pediatric plan.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in CMC comparability package for a site change, then the action for CMC change-control owner - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - CMC and Development Pathways finding in CMC comparability package for a site change that a second reviewer can re-perform - Missing page in CMC comparability package for a site change after a boxed-warning proposal from the review division, if any